17,261 trials
WHIM Syndrome
Primary: Mean Value of the Area Under the Plasma Concentration-time Curve for Absolute Neutrophil Count (AUCANC) — -12574.63; -6206.75; -6949.58; 24175.00 cells*hour/μL
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Crohn's Disease
Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12…
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) by BICR Based on IWG Criteria — 78.3; 64.2; 73.3 Percentage of participants
Primary Sjogren Syndrome
Primary: Least Squares Mean Change From Baseline in ESSDAI Score at Week 24 — -6.39; -5.64; -6.93; -8.30 Scores on a scale — p=0.5161
Ulcerative Colitis
Primary: Percentage of Participants Who Achieved Clinical Remission at Week 12 — 0; 6.7; 26.3 Percentage of participants
Sickle Cell Disease · Sickle-Cell; Hemoglobin Disease, Thalassemia · Sickle Cell-beta-thalassemia
Primary: Clearance (CL/F) — 3.61 L/hr
Influenza Viral Infections
Primary: Incidence of Symptomatic Influenza Infection — 6; 6; 16; 12 Participants — p=0.0331
Postoperative Pain
Primary: Total Opioid Requirement — 3.31; 5.27; 10.2; 4.1 OME/kg/d
Infections and Infestations · Pulmonary Tuberculosis
Primary: Safety Outcome : Proportion of Patients Experiencing Adverse Event — 8; 7; 7; 6 Participants
Tobacco Dependence
Primary: Treatment Satisfaction — 38; 44; 56 Participants
Cancer
Primary: Number of Participants and Type of Reported Adverse Events — 25; 22; 22; 6 Participants
Heart Failure
Primary: Change in the Health Self-Care Neglect (HSCN) Scale — 4.89; 4.97; 3.09; 3.50 score on a scale — p=0.04
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 14.2; 4.4 Months